Skip to main content

Evaluation of the inactivation / removal effect of the gelatin manufacturing process on tse infectivity

Objective

For the manufacture of bone gelatine a downscaled Pilot model has been developed and tested to reflect as close as possible the industrial processes and to represent the typical manufacturing conditions. Spiking crushed fresh bone with 30 I V infected mouse brain (BSE agent) and 263 K infected hamster brain (scrape agent) and processing these materials through the downscaled model to produce gelatin. Using the processed material from the whole process to determine the residual infectivity of gelatine and declaim-phosphate by bioassay. Evaluating separately the inactivation capacity on individual process steps of the finishing unit operations by spiking the industrial starting material and processing this material through these steps and measuring the remaining infectivity. In total 17 samples are prepared and submitted to bioassay. All samples are additionally tested by immunoblotting.

Funding Scheme

DEM - Demonstration contracts

Coordinator

DELFT GELATIN B.V.
Address
Rotterdamseweg 270
2600 AA Delft
Netherlands

Participants (2)

ID LELYSTAD - INSTITUTE FOR ANIMAL HEALTH AND SCIENCE
Netherlands
Address
Edelhertweg 15
8219 PH Lelystad
INSTITUTE FOR ANIMAL HEALTH
United Kingdom
Address
Compton Laboratory, Compton
RG20 7NN Newbury